Pancreatic Cancer Research

ResearcherTexas A&M UniversityActive in the last 2 years

Mingyao Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7339-5048; OpenAlex author ID A5100709239. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers

Papers 9

  1. Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. Last author DOI 10.1021/acscentsci.3c01440↗
  2. Correction: Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Co-author DOI 10.1038/s41388-024-03044-x↗
  3. Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-0997↗
  4. Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment. Co-author DOI 10.1021/acs.jmedchem.2c01554↗
  5. A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis. Co-author DOI 10.3390/molecules27041209↗
  6. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Co-author DOI 10.1038/s41388-020-01626-z↗
  7. Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targetin… Co-author DOI 10.1021/acs.jmedchem.9b00059↗
  8. Acetyl-11-keto-β-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. Co-author DOI 10.1002/ijc.25966↗
  9. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor recep… Co-author DOI 10.1111/j.1349-7006.2010.01778.x↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhengfang Yi · 7 shared papers, 2011–2024 · strength 0.90
  2. Chen Huang · 4 shared papers, 2021–2024 · strength 0.66
  3. Yihua Chen · 5 shared papers, 2011–2024 · strength 0.59
  4. Zhenliang Sun · 2 shared papers, 2023–2024 · strength 0.34
  5. Peng He · 2 shared papers, 2022–2024 · strength 0.32
  6. Jiacheng He · 1 shared paper, 2022 · strength 0.13
  7. Weiqiang Lü · 1 shared paper, 2022 · strength 0.13
  8. Xin Wang · 1 shared paper, 2019 · strength 0.08
  9. Yunqi Li · 1 shared paper, 2019 · strength 0.08
  10. Byoungduck Park · 1 shared paper, 2011 · strength 0.03
  11. Sung‐Gook Cho · 1 shared paper, 2011 · strength 0.03
  12. Bharat Bhushan Aggarwal · 1 shared paper, 2011 · strength 0.03
  13. Lijun He · 1 shared paper, 2011 · strength 0.03
  14. Xiufeng Pang · 1 shared paper, 2011 · strength 0.03
  15. Jieqiong Wang · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.